DD209736A5 - Verfahren zur herstellung zell- und geweberegenerierender stoffe - Google Patents

Verfahren zur herstellung zell- und geweberegenerierender stoffe Download PDF

Info

Publication number: DD209736A5
Authority: DD; German Democratic Republic
Prior art keywords: glycolipids; substances; liquid; blood; dialysate
Prior art date: 1982-05-28

Application number

DD83251244A

Other languages

German (de)

English (en)

Inventor

Wolfgang Fraefel

Roland Tschannen

Original Assignee

Solco Basel Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-05-28

Filing date

1983-05-25

Publication date

1984-05-23

1983-05-25 Application filed by Solco Basel Ag filed Critical Solco Basel Ag

1984-05-23 Publication of DD209736A5 publication Critical patent/DD209736A5/de

Links

239000000126 substance Substances 0.000 title claims abstract description 41
238000004519 manufacturing process Methods 0.000 title claims abstract description 6
229930186217 Glycolipid Natural products 0.000 claims abstract description 28
238000000034 method Methods 0.000 claims abstract description 27
210000004369 blood Anatomy 0.000 claims abstract description 14
239000008280 blood Substances 0.000 claims abstract description 14
208000035404 Autolysis Diseases 0.000 claims abstract description 13
206010057248 Cell death Diseases 0.000 claims abstract description 13
230000028043 self proteolysis Effects 0.000 claims abstract description 13
238000000502 dialysis Methods 0.000 claims abstract description 12
239000007858 starting material Substances 0.000 claims abstract description 11
230000008569 process Effects 0.000 claims abstract description 9
210000000056 organ Anatomy 0.000 claims abstract description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
239000000203 mixture Substances 0.000 claims description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
239000007791 liquid phase Substances 0.000 claims description 8
239000012071 phase Substances 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 8
239000003960 organic solvent Substances 0.000 claims description 6
238000000926 separation method Methods 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 5
244000309466 calf Species 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
239000012736 aqueous medium Substances 0.000 claims description 3
239000012074 organic phase Substances 0.000 claims description 3
239000007790 solid phase Substances 0.000 claims description 3
239000011877 solvent mixture Substances 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 2
150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
150000002170 ethers Chemical class 0.000 claims description 2
150000008282 halocarbons Chemical class 0.000 claims description 2
229930195733 hydrocarbon Natural products 0.000 claims description 2
150000002430 hydrocarbons Chemical class 0.000 claims description 2
206010052428 Wound Diseases 0.000 abstract description 19
208000027418 Wounds and injury Diseases 0.000 abstract description 19
238000004587 chromatography analysis Methods 0.000 abstract description 11
241000124008 Mammalia Species 0.000 abstract description 7
239000004480 active ingredient Substances 0.000 abstract description 6
239000012043 crude product Substances 0.000 abstract description 4
230000001172 regenerating effect Effects 0.000 abstract description 3
206010012665 Diabetic gangrene Diseases 0.000 abstract description 2
230000002490 cerebral effect Effects 0.000 abstract description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
208000035475 disorder Diseases 0.000 abstract description 2
238000012869 ethanol precipitation Methods 0.000 abstract description 2
208000030159 metabolic disease Diseases 0.000 abstract description 2
230000005855 radiation Effects 0.000 abstract description 2
206010040943 Skin Ulcer Diseases 0.000 abstract 1
230000001476 alcoholic effect Effects 0.000 abstract 1
238000002481 ethanol extraction Methods 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 52
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
239000000243 solution Substances 0.000 description 20
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
239000000741 silica gel Substances 0.000 description 12
229910002027 silica gel Inorganic materials 0.000 description 12
238000000605 extraction Methods 0.000 description 11
230000035876 healing Effects 0.000 description 10
238000001556 precipitation Methods 0.000 description 10
239000000047 product Substances 0.000 description 10
229960000583 acetic acid Drugs 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
235000002639 sodium chloride Nutrition 0.000 description 8
229910052751 metal Inorganic materials 0.000 description 7
239000002184 metal Substances 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
150000002339 glycosphingolipids Chemical class 0.000 description 6
230000029663 wound healing Effects 0.000 description 6
239000001913 cellulose Substances 0.000 description 5
229920002678 cellulose Polymers 0.000 description 5
235000015110 jellies Nutrition 0.000 description 5
239000008274 jelly Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000003463 adsorbent Substances 0.000 description 4
-1 aliphatic alcohols Chemical class 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000010828 elution Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
108010054147 Hemoglobins Proteins 0.000 description 3
102000001554 Hemoglobins Human genes 0.000 description 3
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
238000004040 coloring Methods 0.000 description 3
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
229960002591 hydroxyproline Drugs 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
210000000438 stratum basale Anatomy 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000013375 chromatographic separation Methods 0.000 description 2
238000010908 decantation Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
238000001035 drying Methods 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
229910000042 hydrogen bromide Inorganic materials 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
244000309715 mini pig Species 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
150000002482 oligosaccharides Chemical class 0.000 description 2
OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
239000003791 organic solvent mixture Substances 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
239000013049 sediment Substances 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000004904 shortening Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000015424 sodium Nutrition 0.000 description 2
VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
241000766026 Coregonus nasus Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
235000005811 Viola adunca Nutrition 0.000 description 1
240000009038 Viola odorata Species 0.000 description 1
235000013487 Viola odorata Nutrition 0.000 description 1
235000002254 Viola papilionacea Nutrition 0.000 description 1
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000003513 alkali Substances 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
239000010951 brass Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000000385 dialysis solution Substances 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000006266 etherification reaction Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000003269 fluorescent indicator Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000004209 hair Anatomy 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
210000001624 hip Anatomy 0.000 description 1
QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000266 injurious effect Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
150000002496 iodine Chemical class 0.000 description 1
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000011147 magnesium chloride Nutrition 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
229910044991 metal oxide Inorganic materials 0.000 description 1
150000004706 metal oxides Chemical class 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
XCWIEIVORUMFMV-UHFFFAOYSA-N methyl 4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C=C1.COC(=O)C1=CC=C(O)C=C1 XCWIEIVORUMFMV-UHFFFAOYSA-N 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
XOOMNEFVDUTJPP-UHFFFAOYSA-N naphthalene-1,3-diol Chemical compound C1=CC=CC2=CC(O)=CC(O)=C21 XOOMNEFVDUTJPP-UHFFFAOYSA-N 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
NJBNJRILTKLNQZ-UHFFFAOYSA-N propyl 4-hydroxybenzoate Chemical compound CCCOC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1 NJBNJRILTKLNQZ-UHFFFAOYSA-N 0.000 description 1
238000004080 punching Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
230000008263 repair mechanism Effects 0.000 description 1
210000001732 sebaceous gland Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
239000004317 sodium nitrate Substances 0.000 description 1
235000010344 sodium nitrate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007447 staining method Methods 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Hematology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Prostheses (AREA)
Materials For Medical Uses (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DD83251244A 1982-05-28 1983-05-25 Verfahren zur herstellung zell- und geweberegenerierender stoffe DD209736A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH332882		1982-05-28

Publications (1)

Publication Number	Publication Date
DD209736A5 true DD209736A5 (de)	1984-05-23

Family

ID=4253592

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD83251244A DD209736A5 (de)	1982-05-28	1983-05-25	Verfahren zur herstellung zell- und geweberegenerierender stoffe

Country Status (18)

Country	Link
US (1)	US4544552A (pl)
EP (1)	EP0095682B1 (pl)
JP (1)	JPS58219120A (pl)
AR (1)	AR231231A1 (pl)
AT (1)	ATE29137T1 (pl)
AU (1)	AU551992B2 (pl)
CA (1)	CA1202894A (pl)
DD (1)	DD209736A5 (pl)
DE (1)	DE3373188D1 (pl)
DK (1)	DK157763C (pl)
ES (1)	ES8407064A1 (pl)
FI (1)	FI77373C (pl)
HU (1)	HU189286B (pl)
NO (1)	NO157144C (pl)
PL (1)	PL142242B1 (pl)
SU (1)	SU1396958A3 (pl)
YU (1)	YU44865B (pl)
ZA (1)	ZA833446B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4699788A (en) *	1984-08-20	1987-10-13	Trustees Of Boston University	Angiogenic factor methods of extraction and method for producing angiogenesis
US4710490A (en) *	1985-10-01	1987-12-01	Angio Medical Corporation	Compositions containing ganglioside molecules with enhanced angiogenic activity
US4767746A (en) *	1985-12-04	1988-08-30	Trustees Of Boston University	Method for enhancement of healing of epithelial wounds in mammals
US4990333A (en) *	1985-12-20	1991-02-05	Angio Medical Corporation	Method for healing bone damage
US4778787A (en) *	1985-12-20	1988-10-18	Trustees Of Boston University	Method for treatment of angina and myocardial infarctions with omental lipids
US4816450A (en) *	1986-09-15	1989-03-28	Duke University	Inhibition of protein kinase C by long-chain bases
US4937232A (en) *	1986-09-15	1990-06-26	Duke University	Inhibition of protein kinase C by long-chain bases
US5019087A (en) *	1986-10-06	1991-05-28	American Biomaterials Corporation	Nerve regeneration conduit
EP0274547A1 (en) *	1986-12-18	1988-07-20	Trustees Of Boston University	Method for enhancement of healing of epithelial wounds in mammals
EP0380558A4 (en) *	1987-09-22	1991-07-31	The Regents Of The University Of California	Liposomal nucleoside analogues for treating aids
US5035901A (en) *	1987-10-09	1991-07-30	University Of Kansas	Bone inducing agent from a human osteosarcoma cell line
US5693620A (en) *	1991-07-31	1997-12-02	Oncomembrane, Inc.	Plasmalopsychosines and plasmalocerebrosides
DE69225712D1 (de) *	1991-07-31	1998-07-02	Oncomembrane Inc	Plasmalopsychosine und plasmalocerebroside und verfahren zur behandlung von neuronalen erkrankungen mit diesen substanzen
EP0645135A1 (de)	1993-09-29	1995-03-29	Solco Basel AG	Hämodialysat enthaltendes Sonnenschutzmittel
EP1349567A4 (en) *	2000-12-08	2005-10-12	Childrens Memorial Hospital	COMPOSITIONS WITH GANGLIOSIDES FOR USE IN THE TREATMENT OF SKIN DISEASES
MX2007013725A (es)	2005-05-05	2008-04-09	Sensient Flavors Inc	Produccion de beta-glucanos y mananos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2912359A (en) *	1955-05-04	1959-11-10	Developments Inc	Wound healing agent obtained from blood and method of preparation
US3526697A (en) *	1966-10-06	1970-09-01	Nevada Pharm Inc	Therapeutic method
JPS5220524B1 (pl) *	1968-11-02	1977-06-04
LU62266A1 (pl) *	1970-12-17	1972-08-23
FR2195425A1 (en) *	1972-08-10	1974-03-08	Manganaro Domenico	Biological products from animal organs - by homogenization proteolysis, acid purification and ultra filtration
CA1168980A (en) *	1980-04-17	1984-06-12	Rolf Schafer	Wound healing compositions

1983
- 1983-05-13 ZA ZA833446A patent/ZA833446B/xx unknown
- 1983-05-18 YU YU1104/83A patent/YU44865B/xx unknown
- 1983-05-18 CA CA000428439A patent/CA1202894A/en not_active Expired
- 1983-05-20 DE DE8383105027T patent/DE3373188D1/de not_active Expired
- 1983-05-20 EP EP83105027A patent/EP0095682B1/de not_active Expired
- 1983-05-20 AT AT83105027T patent/ATE29137T1/de not_active IP Right Cessation
- 1983-05-23 FI FI831827A patent/FI77373C/fi not_active IP Right Cessation
- 1983-05-24 DK DK231683A patent/DK157763C/da not_active IP Right Cessation
- 1983-05-25 DD DD83251244A patent/DD209736A5/de not_active IP Right Cessation
- 1983-05-25 HU HU831840A patent/HU189286B/hu not_active IP Right Cessation
- 1983-05-26 AR AR293151A patent/AR231231A1/es active
- 1983-05-26 US US06/498,468 patent/US4544552A/en not_active Expired - Fee Related
- 1983-05-26 AU AU14994/83A patent/AU551992B2/en not_active Ceased
- 1983-05-27 ES ES522758A patent/ES8407064A1/es not_active Expired
- 1983-05-27 NO NO831894A patent/NO157144C/no unknown
- 1983-05-27 PL PL1983242228A patent/PL142242B1/pl unknown
- 1983-05-27 JP JP58094753A patent/JPS58219120A/ja active Pending
- 1983-05-27 SU SU833598349A patent/SU1396958A3/ru active

Also Published As

Publication number	Publication date
FI831827L (fi)	1983-11-29
EP0095682A3 (en)	1984-06-13
PL142242B1 (en)	1987-10-31
US4544552A (en)	1985-10-01
NO157144C (no)	1988-01-27
DK157763B (da)	1990-02-12
DK231683A (da)	1983-11-29
DK231683D0 (da)	1983-05-24
SU1396958A3 (ru)	1988-05-15
AR231231A1 (es)	1984-10-31
EP0095682B1 (de)	1987-08-26
AU551992B2 (en)	1986-05-15
PL242228A1 (en)	1984-07-02
ZA833446B (en)	1984-02-29
EP0095682A2 (de)	1983-12-07
HU189286B (en)	1986-06-30
YU44865B (en)	1991-04-30
DK157763C (da)	1990-07-09
FI77373B (fi)	1988-11-30
DE3373188D1 (en)	1987-10-01
FI831827A0 (fi)	1983-05-23
YU110483A (en)	1986-02-28
ES522758A0 (es)	1984-08-16
FI77373C (fi)	1989-03-10
ATE29137T1 (de)	1987-09-15
ES8407064A1 (es)	1984-08-16
NO831894L (no)	1983-11-29
AU1499483A (en)	1983-12-01
JPS58219120A (ja)	1983-12-20
NO157144B (no)	1987-10-19
CA1202894A (en)	1986-04-08

Legal Events

Date	Code	Title	Description
1995-06-22	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
EP0095682B1 (de)	1987-08-26	Verfahren zur Herstellung zell- und geweberegenerierender Stoffe
DE2619667C2 (de)	1984-12-06	Pharmazeutisches Mittel
DD157561A5 (de)	1982-11-17	Verfahren zur herstellung von mucopolysacchariden
DE2456589C2 (de)	1983-12-29	Verfahren zur Herstellung eines Plasminogen-Aktivators und denselben enthaltendes Mittel
DE1949195A1 (de)	1970-07-30	Verfahren zur Herstellung deproteinisierter Bluextrakte mit Heilwirkung
DE3306944C2 (pl)	1989-04-13
DE2605576C3 (de)	1981-04-30	Verfahren zum Isolieren der Proteasen Papain,,Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und Iyophilisirten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten
EP0220453A2 (de)	1987-05-06	Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung
DE1076888B (de)	1960-03-03	Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke
CH404858A (de)	1965-12-31	Verfahren zur Herstellung von wachstumfördernde Stoffe enthaltenden Präparaten
DE2234832C2 (de)	1986-02-13	Proteinfreies Hormonkonzentrat von Säugetier-Nebenschilddrüsen, dessen Herstellung und dieses Hormonkonzentrat enthaltende pharmazeutische Präparate
DE2442995C2 (de)	1982-06-09	Proteasefreie Kallikreinlösungen, ein Verfahren zu ihrer Herstellung aus gereinigtem Kallikrein und ihre Verwendung als Arzneimittel
CH634854A5 (de)	1983-02-28	Verfahren zur herstellung organopeptidhaltiger substanzen mit insulinaehnlicher wirksamkeit aus blut oder blutbestandteilen.
DE2806181C2 (de)	1985-10-24	Polysaccharid, Verfahren zu dessen Herstellung und Arzneimittel, das dieses Polysaccharid enthält
DE1617279C3 (de)	1980-04-24	Verfahren zur Herstellung eines die Aspergillopeptidase ARL 1 enthaltenden Präparates aus Aspergillus oryzae und sie enthaltendes Arzneimittel
EP0189485A1 (de)	1986-08-06	Hexapeptid
EP0075925B1 (de)	1991-01-02	Verfahren zur Herstellung eines spezifisch auf das Ernährungszentrum wirkenden appetitregelnden Wirkstoffes sowie der nach diesem Verfahren erhältliche Wirkstoff
DE69308211T2 (de)	1997-07-10	Stofffamilie mit porphinring, ihre verfahren zur herstellung aus cyanophyceen und ihre verwendungen als kosmetika oder arzneimittel
AT392003B (de)	1991-01-10	Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat
DE1293705B (de)	1969-04-30	Verfahren zur Gewinnung eines elastolytisch wirksamen Bauchspeicheldruesen-Praeparates
WO1990010452A1 (de)	1990-09-20	Proteinfraktion aus dem photosyntheseapparat von pflanzen zur anwendung als wirkstoff zur selektiven auflösung von krebszellen und zur nachbehandlung von narben, keloiden und entzündlichen prozessen sowie diese enthaltende pharmazeutische erzeugnisse
DE2702075C2 (de)	1984-01-12	Hydrolytisches Enzym und dieses enthaltendes Arzneimittel
AT200257B (pl)	1958-10-25
DE2426584A1 (de)	1975-01-09	Substanz zur heilung von leberschaeden und verfahren zu deren herstellung aus protein-bruehen
WO1990000898A1 (de)	1990-02-08	Oberflächenaktives und biologisch aktives präparat